faculty portrait if available
Keith Jackson
Associate Professor
School Basic Pharm & Toxicol Sci
PHAR 370
318-342-1390
ULM logo

Keith E Jackson, PhD
Associate Professor, Pharmacy

Education

Ph D

2001, Integrative Physiology
UNTHSC

BS

1994, Premedicine/Biology
Southern University

Biographical Sketch

Keith E. Jackson Sr is an Associate Professor of Pharmacology at the University of Louisiana at Monroe College of Pharmacy. Prior to joining the College of Pharmacy family he was an instructor at the Tulane University Health Sciences center and a postdoctoral fellow at the Tulane University HSC for two years and the University of North Texas HSC for one year.

Dr. Jackson’s research aims at understanding the controlling mechanisms, which lead to the development and maintenance of an elevation in mean arterial pressure in hypertension.  In this regard an emphasis has been placed on an integrative study of cardiovascular and renal functional changes that occur during an elevation in blood pressure. The current research studies have the following aims:

  1. Find the major hormonal and neuronal controllers for the development of hypertension.
  2. Understand changes in cardiovascular function and renal hemodynamics that occur prior to the development of hypertension.
  3. Develop an understanding of why an imbalance in electrolyte homeostasis exists in hypertension.
  4. Develop new strategies for the treatment of hypertensive patients.

Dr. Jackson enjoys research and discovering new strategies for the treatment of hypertension, but he also has a passion for teaching and mentoring. To this end he has been a mentor to a number of students at a variety of education levels and has won several teaching and service awards.

Dr. Jackson earned a BS degree in Pre Medicine Biology from the Southern University and A & M in Baton Rouge, Louisiana and went on to earn a Ph.D. degree from the University of North Texas Health Science Center at Fort Worth.

Dr. Jackson is currently engaged in teaching, writing books and researching in several areas of physiology at the University of Louisiana at Monroe College of Pharmacy.

Licensure & Certification

Control Substance Certification, US Department of Justice. (November 07 2019 - December 31 2020)
Louisiana Controlled Dangerous Substance License, Louisiana Board of Pharmacy. (December 08 2019 - December 08 2020)
Control Substance Certification, US Department of Justice. (November 07 2018 - December 31 2019)
Louisiana Controlled Dangerous Substances License, Louisiana Board of Pharmacy. (December 08 2018 - December 08 2019)
Control Substance Certification, US Department of Justice. (November 07 2017 - December 31 2018)
Louisiana Controlled Dangerous Substances License, Louisiana Board of Pharmacy. (December 08 2017 - December 08 2018)
Control Substance Certification, US Department of Justice. (November 07 2016 - December 31 2017)
Louisiana Controlled Dangerous Substances License, Louisiana Board of Pharmacy. (December 08 2016 - December 08 2017)

Research Interests

Hypertension is known as the “silent killer” and it affects more than 65 million Americans, but over 20 million of them don't know it.  Hypertension goes unnoticed in its early onset, because affected individuals initially feel no adverse symptoms. Unfortunately even though hypertensive individuals don’t have outward signs and symptoms, serious medical consequences are occurring during this silent phase of hypertension.

Currently our laboratory is studying the role of carbon monoxide in angiotensin II dependent hypertension. Angiotensin II is a hormone produced in the body that promotes potent vascular vasoconstriction and salt and water retention. Angiotensin II levels have been reported to be abnormally elevated in several forms of hypertension. Current literature supports a role for angiotensin II leading to the deleterious end-organ damage and medical crisis seen in hypertensive patients.

Carbon monoxide is an endogenous gas produced in the body and has been demonstrated to produce smooth muscle dependent vasodilation and endothelial dependent vasoconstriction. Angiotensin II has been shown to upregulate carbon monoxide production, yet the role of carbon monoxide in angiotensin II dependent hypertension has yet to be elucidated. Thus, our laboratory is zealously studying carbon monoxide and its potential as a novel treatment strategy to help eradicate the hypertensive disorder.

Recent Publications

Aryal, D., Roy, T., Chamcheu, J., Jackson, K. E. (2021). Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress (pp. 1-15). Antioxidants.
Aryal, D., Jackson, K. E. (2020). Association of acid-base balance in the renal proximal tubule and blood pressure alterations; role of local mediators (pp. 26-44). J of Bios and Med.
Christian, O. E., Jackson, K. E., Somnath, M. (2019). Antihypertensive and Anti-inflammatory Potential of the Edible Fruit of Artocarpus altilis (Breadfruit) (pp. 1-6). Clin Pharmacol Toxicol J.
Fakhruddin, S., Alanazi, W., Alhamami, H. N., Briski, K. P., Jackson, K. E. (2018). Hyperglycemia induced by chronic I.P. and oral glucose loading leads to hypertension through increased Na+-retention in proximal tubule (pp. 236-249). Exp Physiol.
Fakhruddin, S., Alanazi, W., Jackson, K. E. (2017). Development of a chronic hyperglycemic and hypertensive rat model through repetitive intraperitoneal and oral glucose loading (pp. 48783-93). Int J of Current Res..
Prathipati, P., Jackson, D. W., Jackson, K. E. (2017). Evaluating the significance of hypoglycemia in promoting insulin induced hypertension by using a glucose clamp model (pp. 22-27). Int J Med..
Fakhruddin, S., Alanazi, W., Jackson, K. E. (2017). Diabetes-induced reactive oxygen species (ROS): Mechanism of their generation and role in Renal Injury (pp. 1-30). J Diabetes Res.
Alanazi, W., Uddin, M., Fakhruddin, S., Jackson, K. E. (2017). Recurrent insulin-induced hypoglycemia induces AngII and COX2 leading to renal (pro)renin receptor expression and oxidative stress (pp. 71-78). Int J Med.
Alanazi, W., Fakhruddin, S., Jackson, K. E. (2016). The role of recurrent insulin-induced hypoglycemia on renal prostanoid production (pp. 1-9). Annu Res & Rev in Biol.
Christian, K. R., Pothu, S., Nair, M. G., Prathipati, P., Jackson, K. E., Christian, O. E. (2016). Antihypertensive, antiinflammatory and antioxidant activities of breadfruit leaf tea (pp. 29-33). Current topics in Phytochemistry.
Alanazi, W., Fakhruddin, S., Jackson, K. E. (2016). Acute angiotensin II infusion promotes local production of prostaglandin E2 and reactive oxygen species in the renal cortex (pp. 146-151). Innovative J Med Health Sci..
Alanazi, W., Fakhruddin, S., Jackson, K. E. (2015). Microdialysis sampling of renal interstitial fluid in acute studies (pp. 69-79). Int J Biol.
Prathipati, P., Alanazi, W., Fakhruddin, ., Jackson, D. W., Jackson, K. E. (2015). Role of interstitial angiotensin II and ATP in mediating renal injury induced by recurrent insulin induced hypoglycemia (pp. 328-336). Annu Res & Rev in Biol.
Quadri, S., Prathipati, P., Jackson, D. W., Jackson, K. E. (2014). Regulation of heme oxygenase-1 induction during recurrent insulin induced hypoglycemia (pp. 47-52). Int J Med.
Prathipati, P., Quadri, S., Jackson, D. W., Jackson, K. E. (2014). Role of Nitric Oxide in Septal Coronary Arteries of Obese Zucker Rats (pp. 8-12). Int J Med..
Quadri, S., Prathipati, P., Jackson, D. W., Jackson, K. E. (2014). Hemodynamic Consequences of Recurrent Insulin-Induced Hypoglycemia (pp. 81-8). Clin Exp Pharmacol Physiol..
Jackson, D. W., Jackson, K. E. (2013). Using Metagenomics to Teach Biodiversity (pp. 1000). J Ecosys Ecograph..
Quadri, S., Jackson, D. W., Prathipati, P., Jackson, K. E. (2013). Augmentation of Heme Oxygenase Promotes Acute Angiotensin II Induced Hypertension (pp. 21-43). Clin Exp J Med Sci..
Jackson, D. W., Jackson, K. E. (2012). Ecology as a Tool for Basic Research and Clinical Application (pp. 1-2). J Ecosys Ecograph.
Prathipati, P., Quadri, S., Jackson, D. W., Jackson, K. E. (2012). Adaptation of Renal Microdialysis for Chronic Interstitial Collection of Angiotensin II and ATP (pp. 127-136). Int J Biol.
Quadri, S., Jackson, D. W., Prathipati, P., Dean, C., Jackson, K. E. (2012). Heme induction with delta-aminolevulinic acid stimulates an increase in water and electrolyte excretion (pp. 1-8). Int J Hypertens..
Jackson, K. E., Jackson, D. W., Quadri, S., Reitzell, M. J., Navar, L. G. (2011). Inhibition of heme oxygenase augments tubular sodium reabsorption (pp. F941-6). Am J Physiol Renal Physiol..
Graciano, M. L., Nishiyama, A., Jackson, K. E., Seth, D. M., Ortiz, R. M., Prieto-Carrasquero, M., Kobori, H., Navar, L. G. (2008). Purinergic Receptors Contribute to Early Mesangial Cell Transformation and Renal Vessel Hypertrophy during Angiotensin II-Induced Hypertension. (pp. F161-F169). Am J Physiol Renal Physiol..
Johnson, F. K., Johnson, R. A., Durante, W., Jackson, K. E., Stevenson, B. K., Peyton, K. J. (2006). Metabolic syndrome increases endogenous carbon monoxide production to promote hypertension and endothelial dysfunction in obese Zucker rats. (pp. R601-8). Am J Physiol Regul Integr Comp Physiol.
Nishiyama, A., Jackson, K. E., Majid, D. S., Rahman, M., Navar, L. G. (2006). Renal interstitial fluid ATP responses to arterial pressure and tubuloglomerular feedback activation during calcium channel blockade. (pp. H772-7). Am J Physiol Heart Circ Physiol..
Teran, F. J., Johnson, R. A., Stevenson, B. K., Peyton, K. J., Jackson, K. E., Appleton, S. D., Durante, W., Johnson, F. K. (2005). Heme oxygenase-derived carbon monoxide promotes arteriolar endothelial dysfunction and contributes to salt-induced hypertension in Dahl salt-sensitive rats. (pp. R615-22). Am J Physiol Regul Integr Comp Physiol.
Majid, D. S., Nishiyama, A., Jackson, K. E., Castillo, A. (2005). Superoxide scavenging attenuates renal responses to angiotensin ii during nitric oxide synthase inhibition in anesthetized dogs. (pp. F412-9). Am J Physiol Renal Physiol..
Majid, D. S., Nishiyama, A., Jackson, K. E., Castillo, A. (2004). Inhibition of nitric oxide synthase enhances superoxide activity in canine kidney. (pp. R27-32). Am J Physiol Regul Integr Comp Physiol..
Farias III, M., Jackson, K. E., Johnson, M., Caffrey, J. L. (2003). Cardiac Enkephalins Attenuate Vagal Bradycardia: interactions with the NOS-1, cGMP System in the Canine Sinoatrial Node. (pp. H2001-12). Am J Physiol Heart Circ Physiol..
Stanfill, A. A., Jackson, K. E., Farias, M., Barlow, M., Deo, S., Johnson, S., Caffrey, J. L. (2003). Leucine-enkephalin interrupts sympathetically mediated tachycardia prejunctionally in the canine sinoatrial node. (pp. 898-906). Exp Biol Med (Maywood)..
Farias, M., Jackson, K. E., Yoshishige, D., Caffrey, J. L. (2003). Bimodal {delta}-opioid receptors regulate vagal bradycardia in canine sinoatrial node. (pp. H13332-H1339). Am J Physiol Heart Circ Physiol..
Farias III, M., Jackson, K. E., Yoshishige, D., Caffrey, J. L. (2003). Cardiac Enkephalins Interrupt Vagal Bradycardia Via {delta}-2-Opioid Receptors in the Sinoatrial Node. (pp. H1693-701). Am J Physiol Heart Circ Physiol..
Jackson, K. E., Farias, M., Stanfill, A. S., Caffrey, J. L. (2001). Transient arterial occlusion raises enkephalin in the canine sinoatrial node and improves vagal bradycardia. (pp. 84-92). Auton Neurosci..
Jackson, K. E., Farias, M., Stanfill, A., Caffrey, J. L. (2001). Delta opioid receptors inhibit vagal bradycardia in the sinoatrial node. (pp. 385-93). J Cardiovasc Pharmacol Ther..
Farias, M., Jackson, K. E., Stanfill, A., Caffrey, J. L. (2001). . Local opiate receptors in the sinoatrial node moderate vagal bradycardia. (pp. 9-15). Auton Neurosci..
Jackson, K. E., Farias, M., Caffrey, J. L. (2000). Cardiac microdialysis a powerful tool (pp. 367-9). Cardiovasc Res..
Napier, L. D., Stanfill, A., Yoshishige, D. A., Jackson, K. E., Barron, B. A., Caffrey, J. L. (1998). Autonomic control of heart rate in dogs treated chronically with morphine (pp. H2199-210). Am J Physiol Heart Circ Physiol..

Research Grants

Jackson, K. E. (Principal), Walker, A. (Co-Principal), Chamcheu, J. C. (Co-Principal), "Improved Access to Health Care in Northeast Louisiana" (Funded), Sponsored By Blue Cross, External to The University of Louisiana at Monroe, $2,000. (January 2019 - December 31 2022).
Jackson, K. (Principal), Walker, A. (Supporting), Chamcheu, J. C. (Supporting), "Promotion of Enhanced Health Care" (Funded), Sponsored By Living Well, External to The University of Louisiana at Monroe, $15,000. (January 2019 - December 2020).
Jackson, K. E. (Principal), "Role of Heme Oxygenase in the Renal Control of Hypertension" (Funded), Sponsored By NIH/LSU INBRE, The University of Louisiana at Monroe, $50,000. (April 01 2015 - November 30 2016).

Awards & Honors

May 2009 StarFellow.

September 2005 International Union of Physiological Sciences Travel Award.

April 2005 Minority Travel Fellowship.

April 2005 Carolina Tum Suden Professional Opportunity Award.

March 2005 SSCI/SAFMR Trainee Research Award.

April 2004 Minority Travel Fellowship.

January 2004 National Research Service Award.

April 2003 Minority Travel Fellowship.

March 2003 SSCI/SAFMR Trainee Research Award.

June 2001 Travel Award International Narcotics Research Conference.

May 2001 Graduate Student of the Year.

May 2001 Graduate Student of the Year.

April 2001 Minority Travel Fellowship.

June 2000 Travel Award International Narcotics Research Conference.

April 2000 Minority Travel Fellowship.

April 2000 Outstanding Community Leader.

April 1999 Minority Travel Fellowship.

January 1996 Graduate Fellowshipp.

May 1991 Outstanding Freshman of the Year.

November 1990 Runner up for Best Oral Presentation in Toxicology.

June 1990 National Dean's List.

Courses Taught

PHAR 5010ADVANCED CV PHYSIOLOGY, 7 course(s)

PHAR 5016STERILE PRODUCTS, 1 course(s)

PHRD 4012PATHOPHYSIOLOGY I, 4 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 4 course(s)

PHRD 4035PATHOPHYSIOLOGY II, 9 course(s)

PHRD 4058NEUROLOGY & PSYCHIATRY MODULE, 5 course(s)

PHRD 4064THERAPEUTICS I, 3 course(s)

PHRD 4093THERAPEUTICS IV, 3 course(s)

PHRD 5010CARDIOVASCULAR MODULE, 6 course(s)

PHRD 5014THERAPEUTICS V, 2 course(s)

PHRD 5033RENAL/UROLOGY MODULE, 5 course(s)